The 24th Regional Congress of the ISBT (International Society of Blood Transfusion)
took place in Kuala Lumpur (Malaysia) from december 1st to 4th. It was the first time that Macopharma was present significantly !
Macopharma had the pleasure to welcome some customers from China, Malaysia, Philippines, India, Poland, Thailand, South Korea and many more countries.
It was an good opportunity to present our products and meet some potential customers or distributors.
The next event of the ISBT will be the 33rd international congress and will be held in Seoul (South Korea) between May 31st and June 5th 2014.Véronique Lutun – Communication Manager
Macopharma SA (“Macopharma”), an innovator in global healthcare and provider of transfusion, infusion and cellular therapy products and solutions, is proud to announce the creation of a new subsidiary in India.
The opening of an office in New Delhi, is a strategic initiative in order to promote our products and technology all over the Asian area.
The official address in India is :
Macopharma India Transfusion Solution Pvt. Ltd.
DLF Tower A, 6th floor, Unit 617, N.H. Commercial Centre Jasola
Tel : +91 11 -4209 1900 / Fax : +91 11-4209 1999
Mobile : +91 98 1056 5080
This subsidiary will offer Macopharma a competitive advantage on the challenging market to increase our sales and partnership meanwhile to reinforce our global presence in the world of transfusion.
Mr Mannoj Panwar, will establish the infrastructure for the subsidiary and eventually will assemble his team to assist him in the development of this market.
ABOUT MACOPHARMA SA
Macopharma SA (“Macopharma”) (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. It has become the largest supplier of in-line leucoreduction filtration sets in Europe and is expanding its efforts into the cellular therapy field by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has three manufacturing facilities in Europe and their products are sold into more than 55 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with the Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion and cellular therapyVéronique Lutun – Communication Manager
Partnership between Macopharma and Diagast in Germany, Austria and Switzerland
Macopharma started a new partnership in the German speaking area.
Diagast designs, produces, and supplies immunhaematology products.
It focuses on two main activities: transfusion and distribution.
Our common ambition is to combine best product quality with ideal customer service.
(Advancing Transfusion and Cellular Therapies Worldwide) in Denver.Véronique Lutun – Communication Manager
MacoPharma attended the 32nd South African National Blood Transfusion Congress with his Local partner Haemotec.
Between 400 and 500 delegates from South Africa and foreign countries were present.Véronique Lutun – Communication Manager
To allow a better visibility of the frozen tissue inside the storage kit CDR8000AU, the white internal pot is now replaced by a transparent one.
Go to Blood Safety Website, for having all news about this part of our activity
for extracorporeal photochemotherapy
Macopharma would like to thank our customers, distributors and partners all around the world that have strongly shown a big interest for all our products
Macopharma is pleased to announce FDA clearance on a supplemental new drug application (sNDA) for the “Leucoflex CGP Leukocyte Reduction in-line Filter”.
The “Leucoflex CGP in-line Filter” consists of a blood collection system with 70ml of CPD for the collection of 500±50ml of whole blood and 110ml of AS-1 Additive Solution and is intended for the leukocyte reduction of Red Blood Cells prepared from whole blood stored at 1 -6°C up to 24 hours after collection.
Macopharma has demonstrated for years its expertise in the field of in-line filtration. Our research teams have developed systems that simplify leukocyte reduction process which improve the quality of the recovered blood components, minimise the risks of alloimmunisation, febrile non haemolytic transfusion reactions, post operative infection, immunomodulation, viral contamination (CMV, HTLV…), bacterial contamination and potential white cell-associated prion load.
Macopharma USA, exclusive importer and distributor of Macopharma products in the USA, is proud to now offer the” Leucoflex CGP Leukocyte Reduction in-line Filter” as an efficient solution for cold filtration and high plasma recovery.